Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Lilly Endowment Inc. reported the sale of 101,420 shares of Eli Lilly & Co. (LLY) on 10/08/2025 via multiple transactions at weighted-average prices in the range of $848.00 to $856.00. After these disposals, the reporting person shows beneficial ownership of 94,547,580 shares, held indirectly. The filing is a standard Section 16 Form 4 showing routine disposition activity by an entity identified as a director-related reporting person; the signature is provided by a vice president acting on behalf of the endowment.
Lilly Endowment Inc. reported a sale of 26,795 shares of Eli Lilly & Co. common stock on 10/07/2025. The shares were sold at a weighted average price of $848.009, with individual trade prices ranging from $848.00 to $848.32. After the transaction the reporting person beneficially owned 94,649,000 shares, held directly. The Form 4 was signed by Peter A. Buck on 10/08/2025. The filing discloses no derivative holdings and includes an offer to provide a breakdown of the number of shares sold at each price within the reported range.
Lilly Endowment Inc., a reporting person and director-related holder, sold a total of 161,183 shares of Eli Lilly & Co (LLY) on 10/06/2025. The Form 4 lists eight separate sale line items with weighted-average prices reported in footnotes, ranging across price bands from $848.00 up to $856.375. After these transactions, the reporting person’s beneficial ownership is shown as 94,675,795 shares (reported as direct ownership). The Form 4 is signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc., and discloses that full per-price breakdowns are available upon request.
Lilly Endowment Inc. reported multiple open-market disposals of Common Stock of Eli Lilly & Co (LLY) executed on 10/03/2025. The filings list a sequence of sales that reduced beneficial ownership from 95,025,096 shares to 94,836,978, a net decrease of 188,118 shares. Individual sale lots ranged from 200 to 31,102 shares at reported weighted-average prices in successive buckets from $821.00 up to $847.63, with explanatory footnotes showing transaction price ranges within each bucket. The Form 4 is signed by Diane M. Stenson on behalf of Lilly Endowment Inc.
Eli Lilly & Co (LLY) submitted a Form 144 notice reporting a proposed sale of 300,000 shares of common stock through Fidelity Capital Markets with an indicated aggregate market value of $251,961,000 and an approximate sale date of 10/06/2025 on NYSE/NASDAQ.
The filing shows these shares were originally received as a gift on 02/10/1948 from the J.K. Lilly Sr. Trust. The document also lists multiple prior sales by Lilly Endowment Inc. during 07/24/2025–10/03/2025 that together generated substantial gross proceeds (individual entries up to $284,653,451.48). The signer certifies no undisclosed material adverse information.
This Schedule 13G/A reports that Eli Lilly & Co. and Eli Lilly S.A. filed an amendment concerning their holdings in Immunocore Holdings plc ordinary shares (CUSIP 54258D105) related to the reporting event dated 09/30/2025. Both reporting entities state they beneficially own 0 ordinary shares, representing 0.0% of the class, with 0 shares of sole or shared voting or dispositive power. The filing lists issuer headquarters at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, UK. Signatures show the amendment was executed by Christopher Anderson as Attorney-in-Fact for both filers on 10/03/2025, and reference previously filed powers of attorney incorporated by reference.
This Schedule 13G/A reports that Eli Lilly & Co. and Eli Lilly S.A. filed an amendment concerning their holdings in Immunocore Holdings plc ordinary shares (CUSIP 54258D105) related to the reporting event dated 09/30/2025. Both reporting entities state they beneficially own 0 ordinary shares, representing 0.0% of the class, with 0 shares of sole or shared voting or dispositive power. The filing lists issuer headquarters at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, UK. Signatures show the amendment was executed by Christopher Anderson as Attorney-in-Fact for both filers on 10/03/2025, and reference previously filed powers of attorney incorporated by reference.
Lilly Endowment Inc. reported the sale of 112,596 shares of Eli Lilly & Co. (LLY) common stock on 10/02/2025. The Form 4 lists multiple sale (S) transactions with weighted-average prices reported per line ranging from about $821.09 to $833.92 and transaction price ranges across the trades between $821.00 and $834.23. After the reported sales, the filing shows the reporting person beneficially owned 95,029,382 shares, held directly. The form is signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc., dated 10/03/2025. The filing provides weighted-average prices and footnotes saying the filer will supply per-price breakdowns on request.
Lilly Endowment Inc., a reporting person and director for Eli Lilly & Co (LLY), sold a total of 215,822 shares of Eli Lilly common stock on 10/01/2025 across multiple transactions. The sales occurred at weighted‑average prices reported per lot, with transaction price ranges disclosed between $807.85 and $833.155. After these transactions the reported beneficial ownership held indirectly by the reporting person was 95,141,978 shares. The Form 4 covers transactions numbered 31–55 of 55 total for that reporting day and was signed by Diane M. Stenson as Vice President & Treasurer on behalf of Lilly Endowment Inc.
Eli Lilly (LLY) Form 144 notifies the market of a proposed sale of 305,000 shares of common stock through J.P. Morgan Securities, with an indicated aggregate market value of $251,753,100 and an approximate sale date of 10/02/2025. The filing shows these shares were originally acquired as a gift from the J.K. Lilly Sr. Trust (acquisition date listed as 02/10/1948) and reports prior institutional sales by Lilly Endowment Inc. totaling 875,000 shares across five trades in July–October 2025, generating about $696,456,589 in gross proceeds. The filer attests no undisclosed material adverse information.
Form 144 notice filed for Eli Lilly & Co (LLY) proposing a sale of common stock. The filer notifies a broker, Fidelity Capital Markets, of an approximate sale of 295,000 shares with an aggregate market value of $225,085,000 and an approximate sale date of 10/01/2025 on NYSE/NASDAQ. The shares were reported as originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust; the acquisition table lists 38,400,000 shares acquired on the donor's 01/21/1937 date. The filing also lists multiple recent sales by Lilly Endowment Inc. in July–October 2025 with individual gross proceeds shown for each trade. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.